ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
The menin fault lines emerge
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
But JNJ-75276617 still has much to prove.
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
